GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities
Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease. But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.